BioWorld

Feb. 7, 2006

QuatRx Files $86M IPO To Push Clinical Development

A month after starting its first Phase III trial, QuatRx Pharmaceuticals Co. filed for its initial public offering, hoping to raise $86.25 million. (BioWorld Today) Read More

Biotech Deals: Focusing On Pharma Relationships

ReNeuron's Results Positive As Stem Cell Meeting Starts

Bush's Proposed Budget Boosts FDA Funds In '07

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 18, 2025.

BIO 2025: Makary lays out FDA’s path, launches pilot review program

BioWorld

On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...

An early stage 85% remissions rate in AML drives Aptevo’s stock surge

BioWorld

An 85% remissions rate was found in updated results from Aptevo Therapeutics Inc.’s ongoing phase Ib/II Ranier study of mipletamig in one of the toughest blood...

3D illustration of a chain of amino acid or biomolecules called protein

Alphadesign: AI creating proteins from scratch

BioWorld Science

The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo...